Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)
China · Delayed Price · Currency is CNY 8.29
-0.07 (-0.84%)
Nov 6, 2026, 3:00 PM CST
SHA:600420 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,118 | 13,546 | 16,014 | 13,130 | 9,346 | 10,650 | |
Market Cap Growth | -20.06% | -15.41% | 21.96% | 40.50% | -12.25% | 9.04% |
Enterprise Value | 9,188 | 11,513 | 13,623 | 10,582 | 10,423 | 12,754 |
Last Close Price | 8.29 | 9.82 | 11.30 | 9.09 | 8.37 | 9.44 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.63 | 14.39 | 14.78 | 18.98 | 14.89 | 18.74 |
Forward PE | - | 11.16 | 11.94 | 10.42 | 10.42 | 10.42 |
PS Ratio | 1.38 | 1.45 | 1.46 | 1.09 | 0.72 | 0.76 |
PB Ratio | 0.70 | 0.86 | 1.05 | 0.92 | 0.77 | 1.03 |
P/TBV Ratio | 0.87 | 1.05 | 1.29 | 1.12 | 0.97 | 1.35 |
P/FCF Ratio | 26.28 | 9.44 | 7.86 | 9.63 | 3.67 | 9.20 |
P/OCF Ratio | 17.83 | 7.98 | 7.10 | 7.63 | 3.27 | 6.34 |
PEG Ratio | - | 0.43 | 0.39 | 0.59 | 0.59 | 0.59 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.14 | 1.23 | 1.25 | 0.88 | 0.80 | 0.92 |
EV/EBITDA Ratio | 7.46 | 6.35 | 5.86 | 5.87 | 6.24 | 6.87 |
EV/EBIT Ratio | 15.92 | 10.34 | 8.78 | 10.76 | 12.39 | 11.83 |
EV/FCF Ratio | 21.72 | 8.03 | 6.69 | 7.76 | 4.09 | 11.01 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.07 | 0.08 | 0.28 | 0.40 |
Debt / EBITDA Ratio | 0.03 | 0.02 | 0.49 | 0.64 | 2.02 | 2.20 |
Debt / FCF Ratio | 0.08 | 0.03 | 0.56 | 0.84 | 1.34 | 3.61 |
Net Debt / Equity Ratio | -0.26 | -0.44 | -0.42 | -0.34 | -0.23 | -0.01 |
Net Debt / EBITDA Ratio | -3.36 | -3.87 | -2.80 | -2.68 | -1.64 | -0.05 |
Net Debt / FCF Ratio | -9.70 | -4.89 | -3.19 | -3.54 | -1.08 | -0.09 |
Asset Turnover | 0.42 | 0.48 | 0.56 | 0.62 | 0.67 | 0.75 |
Inventory Turnover | 2.90 | 3.25 | 3.04 | 3.19 | 2.94 | 2.49 |
Quick Ratio | 1.80 | 2.65 | 2.09 | 2.15 | 2.12 | 1.09 |
Current Ratio | 3.40 | 3.59 | 2.69 | 2.82 | 2.79 | 1.59 |
Return on Equity (ROE) | 4.04% | 7.33% | 8.98% | 7.28% | 7.70% | 8.13% |
Return on Assets (ROA) | 1.86% | 3.55% | 4.94% | 3.15% | 2.72% | 3.61% |
Return on Invested Capital (ROIC) | 4.74% | 10.86% | 13.49% | 9.14% | 7.54% | 9.56% |
Return on Capital Employed (ROCE) | 3.60% | 6.90% | 9.90% | 6.30% | 5.50% | 8.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.06% | 6.95% | 6.77% | 5.27% | 6.72% | 5.34% |
FCF Yield | 3.80% | 10.59% | 12.72% | 10.38% | 27.27% | 10.88% |
Dividend Yield | 3.62% | 2.97% | 2.51% | 1.02% | 1.25% | 0.96% |
Payout Ratio | 73.66% | 45.44% | 27.75% | 27.37% | 29.42% | 37.39% |
Buyback Yield / Dilution | -0.00% | 0.00% | -5.31% | -10.13% | 1.82% | 0.14% |
Total Shareholder Return | 3.62% | 2.97% | -2.80% | -9.11% | 3.07% | 1.10% |